Advancing Treatment of EGFR-Positive Metastatic Non-Small Cell Lung Cancer : Episode 7

Impact of Emerging Therapies on Outcomes for EGFR-Mutated NSCLC

July 12, 2024

Opinion

Video

Alan Chin, PharmD, BCOP, examines the PALOMA-3 trial's influence on the treatment of EGFR-mutated metastatic NSCLC and explores the evolving role of antibody-drug conjugates (ADCs) in the therapeutic landscape of EGFR-mutated NSCLC.

EP: 1.Exploring EGFR Mutations and Prevalence in Non-Small Cell Lung Cancer

EP: 2.Examining Key Data from the FLAURA2 and MIRAPOSA Trials

EP: 3.Analyzing the MARIPOSA-2 Trial Data’s Impact on Clinical Practice

EP: 4.Exploring Key Insights from the PAPILLON Trial

EP: 5.Common Adverse Reactions to EGFR Therapy

EP: 6.Expert Insights on Managing Amivantamab Infusion Reactions, Dosing, and Medication

Now Viewing

EP: 7.Impact of Emerging Therapies on Outcomes for EGFR-Mutated NSCLC

How might the advent of subcutaneous amivantamab, currently being studied in the PALOMA-3 trial, impact the treatment of EGFR-mutated metastatic NSCLC? What opportunities or challenges might this impose?
How do you see the role of antibody-drug conjugates (ADCs) evolving in the treatment landscape of EGFR-mutated NSCLC, and are there any in the pipeline that you are particularly excited about?